Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9067214 | 1.00 | POLB (0.53) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL3282256 | 1.00 | POLB (0.53) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL5938686 | 1.00 | POLB (0.53) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL13324264 | 1.00 | POLB (0.53) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL18769553 | 0.86 | ALDH1A1 (0.49) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL31629999 | 0.82 | PKM (0.61) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL29657316 | 0.82 | PKM (0.61) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL9066623 | 0.82 | PKM (0.50) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL9066627 | 0.82 | PKM (0.50) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL18769554 | 0.81 | POLB (0.49) | POLBPKMALDH1A1HTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | DART MICHAEL J | 2006-12-21 | — | — | US | disclosed |
| US-7135484-B2 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | POLB 1309/4885PKM 4464/4885ALDH1A1 123/4885 |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | POLB 1309/4885PKM 4464/4885ALDH1A1 123/4885 |
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHAT, CHRNA6 | POLB 1028/4885PKM 4378/4885ALDH1A1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.